dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Vogel-González, Marina |
dc.contributor.author | Talló-Parra, Marc |
dc.contributor.author | Herrera-Fernández, Víctor |
dc.contributor.author | Pérez-Vilaró, Gemma |
dc.contributor.author | Chillon Rodriguez, Miguel |
dc.contributor.author | Nogués, Xavier |
dc.date.accessioned | 2021-07-19T09:59:40Z |
dc.date.available | 2021-07-19T09:59:40Z |
dc.date.issued | 2021-02-09 |
dc.identifier.citation | Vogel-González M, Talló-Parra M, Herrera-Fernández V, Pérez-Vilaró G, Chillón M, Nogués X, et al. Low zinc levels at admission associates with poor clinical outcomes in sars-cov-2 infection. Nutrients. 2021 Feb 9;13(2):562. |
dc.identifier.issn | 2072-6643 |
dc.identifier.uri | https://hdl.handle.net/11351/6175 |
dc.description | Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Clinical outcomes; Zinc |
dc.description.abstract | Background: Zinc is an essential micronutrient that impacts host–pathogen interplay at infection. Zinc balances immune responses, and also has a proven direct antiviral action against some viruses. Importantly, zinc deficiency (ZD) is a common condition in elderly and individuals with chronic diseases, two groups with an increased risk for severe severe coronavirus disease 2019 (COVID-19) outcomes. We hypothesize that serum zinc content (SZC) influences COVID-19 disease progression, and thus might represent a useful biomarker. Methods: We ran an observational cohort study with 249 COVID-19 patients admitted in Hospital del Mar. We have studied COVID-19 severity and progression attending to SZC at admission. In parallel, we have studied severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) replication in the Vero E6 cell line modifying zinc concentrations. Findings: Our study demonstrates a correlation between serum zinc levels and COVID-19 outcome. Serum zinc levels lower than 50 µg/dL at admission correlated with worse clinical presentation, longer time to reach stability, and higher mortality. Our in vitro results indicate that low zinc levels favor viral expansion in SARS-CoV-2 infected cells. Interpretation: Low SZC is a risk factor that determines COVID-19 outcome. We encourage performing randomized clinical trials to study zinc supplementation as potential prophylaxis and treatment with people at risk of zinc deficiency. |
dc.language.iso | eng |
dc.publisher | MDPI |
dc.relation.ispartofseries | Nutrients;13(2) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Zinc - Efectes fisiològics |
dc.subject | COVID-19 (Malaltia) |
dc.subject.mesh | Coronavirus Infections |
dc.subject.mesh | Zinc |
dc.subject.mesh | /pharmacology |
dc.title | Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3390/nu13020562 |
dc.subject.decs | infecciones por Coronavirus |
dc.subject.decs | zinc |
dc.subject.decs | /farmacología |
dc.relation.publishversion | https://www.mdpi.com/2072-6643/13/2/562 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Vogel-González M, Herrera-Fernández V] Laboratory of Molecular Physiology, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. [Talló-Parra M, Pérez-Vilaró G] Molecular Virology Group, Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain. [Chillón M] Departament de Bioquímica i Biologia Molecular, Institut de Neurociències, Edifici H, Universitat Autònoma de Barcelona, Bellaterra, Spain. Unitat Mixta UAB-VHIR, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Institut Català de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [Nogués X] Department of Internal Medicine, Hospital del Mar, Institut Mar d’Investigacions Mediques, Barcelona, Spain |
dc.identifier.pmid | 33572045 |
dc.identifier.wos | 000622953700001 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-106755RB-I00 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PID2019-106959RB-I00 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/CEX2018-000792-M |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PERIS2016-2020/2017SGR909 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/CB16%2F10%2F00245 |
dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00019 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |